AU2015299008B2 - Carrier molecule for antigens - Google Patents

Carrier molecule for antigens Download PDF

Info

Publication number
AU2015299008B2
AU2015299008B2 AU2015299008A AU2015299008A AU2015299008B2 AU 2015299008 B2 AU2015299008 B2 AU 2015299008B2 AU 2015299008 A AU2015299008 A AU 2015299008A AU 2015299008 A AU2015299008 A AU 2015299008A AU 2015299008 B2 AU2015299008 B2 AU 2015299008B2
Authority
AU
Australia
Prior art keywords
lys
thr
ala
gly
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
AU2015299008A
Other languages
English (en)
Other versions
AU2015299008A1 (en
Inventor
Francesco Berti
Roberta COZZI
Guido Grandi
Domenico Maione
Immaculada Margarit Y Ros
Cira Daniela Rinaudo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
GlaxoSmithKline Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Biologicals SA filed Critical GlaxoSmithKline Biologicals SA
Publication of AU2015299008A1 publication Critical patent/AU2015299008A1/en
Application granted granted Critical
Publication of AU2015299008B2 publication Critical patent/AU2015299008B2/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2015299008A 2014-08-05 2015-08-05 Carrier molecule for antigens Expired - Fee Related AU2015299008B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14179945.2 2014-08-05
EP14179945 2014-08-05
PCT/EP2015/068012 WO2016020413A1 (en) 2014-08-05 2015-08-05 Carrier molecule for antigens

Publications (2)

Publication Number Publication Date
AU2015299008A1 AU2015299008A1 (en) 2017-02-23
AU2015299008B2 true AU2015299008B2 (en) 2018-08-02

Family

ID=51298571

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015299008A Expired - Fee Related AU2015299008B2 (en) 2014-08-05 2015-08-05 Carrier molecule for antigens

Country Status (16)

Country Link
US (1) US10245310B2 (enExample)
EP (1) EP3177324A1 (enExample)
JP (1) JP2017523985A (enExample)
KR (1) KR20170039709A (enExample)
CN (1) CN108064174A (enExample)
AR (1) AR101455A1 (enExample)
AU (1) AU2015299008B2 (enExample)
BE (1) BE1022792B1 (enExample)
BR (1) BR112017002183A2 (enExample)
CA (1) CA2957118A1 (enExample)
EA (1) EA201790239A1 (enExample)
IL (1) IL250238A0 (enExample)
MX (1) MX2017001638A (enExample)
SG (1) SG11201700673RA (enExample)
WO (1) WO2016020413A1 (enExample)
ZA (1) ZA201700824B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE045482T2 (hu) * 2005-06-27 2019-12-30 Glaxosmithkline Biologicals Sa Immunogén készítmény
BE1025162B9 (fr) 2016-12-06 2019-01-07 Glaxosmithkline Biologicals Sa Procede de purification pour les polysaccharides capsulaires
IL267709B2 (en) 2016-12-30 2025-04-01 Vaxcyte Inc Polypeptide-antigen conjugates with unnatural amino acids
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
JP2020515629A (ja) * 2017-04-04 2020-05-28 アヴィディア テクノロジーズ， インコーポレイテッド 免疫応答を誘導するためのペプチドベースのワクチン、それらの製造方法および使用
EP3638301A1 (en) 2017-06-16 2020-04-22 GlaxoSmithKline Biologicals S.A. Method of treatment
WO2019217665A1 (en) * 2018-05-09 2019-11-14 West Virginia University Iron-acquisition receptor peptide administration for vaccination against pseudomonas aeruginosa
EP3574915A1 (en) * 2018-05-29 2019-12-04 Neovacs Immunogenic product comprising il-4 and/or il-13 for treating disorders associated with aberrant il-4 and/or il 13 expression or activity
WO2020010000A1 (en) * 2018-07-04 2020-01-09 Sutrovax, Inc. Improved methods for the preparation of immunogenic conjugates
EP4483896A3 (en) * 2018-07-04 2025-04-02 Vaxcyte, Inc. Improvements in immunogenic conjugates
CN108840914B (zh) * 2018-08-13 2022-07-01 内蒙古民族大学 一种具有免疫原性的多肽、其抗体的制备方法以及用途
SG11202110803YA (en) 2019-04-02 2021-10-28 Vaxcyte Inc Optimized cell-free synthesis of invasion plasmid antigen b and related compositions and methods of use
BR112022008761A2 (pt) 2019-11-22 2022-07-26 Glaxosmithkline Biologicals Sa Dosagem e administração de uma vacina de glicoconjugado de sacarídeo
US20230250142A1 (en) * 2020-06-12 2023-08-10 Glaxosmithkline Biologicals Sa Dock tag system
WO2021250625A2 (en) 2020-06-12 2021-12-16 Glaxosmithkline Biologicals Sa Gbs ferritin nanoparticles
CN112979797B (zh) * 2021-04-28 2022-04-01 中国检验检疫科学研究院 一种抗赤羽病病毒单克隆抗体及其制备方法与应用
GB202215634D0 (en) * 2022-10-21 2022-12-07 Glaxosmithkline Biologicals Sa Polypeptide scaffold
AU2023367780A1 (en) 2022-10-25 2025-03-27 Barinthus Biotherapeutics North America, Inc. Self-assembling nanoparticles

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006069200A2 (en) * 2004-12-22 2006-06-29 Novartis Vaccines And Diagnostics Inc. Group b streptococcus
WO2010079464A1 (en) * 2009-01-12 2010-07-15 Novartis Ag Cna_b domain antigens in vaccines against gram positive bacteria
WO2011121576A2 (en) * 2010-04-01 2011-10-06 Novartis Ag Immunogenic proteins and compositions
WO2013030783A1 (en) * 2011-08-30 2013-03-07 Novartis Ag Immunogenic proteins and compositions

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006078318A2 (en) * 2004-07-29 2006-07-27 Novartis Vaccines And Diagnostics Inc. Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
GB0502095D0 (en) * 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
GB0605757D0 (en) * 2006-03-22 2006-05-03 Chiron Srl Separation of conjugated and unconjugated components
US20100150943A1 (en) * 2006-07-26 2010-06-17 Novartis Ag Immunogenic compositions for gram positive bacteria
GB0802503D0 (en) * 2008-02-11 2008-03-19 Novartis Ag Hybrid polypeptide
GB201003333D0 (en) * 2010-02-26 2010-04-14 Novartis Ag Immunogenic proteins and compositions
CN104321335A (zh) * 2012-02-24 2015-01-28 诺华股份有限公司 菌毛蛋白质和组合物

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006069200A2 (en) * 2004-12-22 2006-06-29 Novartis Vaccines And Diagnostics Inc. Group b streptococcus
WO2010079464A1 (en) * 2009-01-12 2010-07-15 Novartis Ag Cna_b domain antigens in vaccines against gram positive bacteria
WO2011121576A2 (en) * 2010-04-01 2011-10-06 Novartis Ag Immunogenic proteins and compositions
WO2013030783A1 (en) * 2011-08-30 2013-03-07 Novartis Ag Immunogenic proteins and compositions

Also Published As

Publication number Publication date
WO2016020413A1 (en) 2016-02-11
KR20170039709A (ko) 2017-04-11
BR112017002183A2 (pt) 2018-01-16
BE1022792A1 (fr) 2016-09-06
CA2957118A1 (en) 2016-02-11
BE1022792B1 (fr) 2016-09-06
US10245310B2 (en) 2019-04-02
MX2017001638A (es) 2017-04-27
ZA201700824B (en) 2019-07-31
IL250238A0 (en) 2017-03-30
US20170224803A1 (en) 2017-08-10
JP2017523985A (ja) 2017-08-24
EP3177324A1 (en) 2017-06-14
AR101455A1 (es) 2016-12-21
SG11201700673RA (en) 2017-02-27
CN108064174A (zh) 2018-05-22
EA201790239A1 (ru) 2017-07-31
AU2015299008A1 (en) 2017-02-23

Similar Documents

Publication Publication Date Title
US10245310B2 (en) Carrier molecule for antigens
CA2596683C (en) Conjugation of streptococcal capsular saccharides
AU2011303478B2 (en) Immunogenic compositions
AU2012335208B2 (en) Carrier molecule comprising a spr0096 and a spr2021 antigen
EP2519265B1 (en) Polysaccharide immunogens conjugated to e. coli carrier proteins
AU2010352695B2 (en) Conjugation of Staphylococcus aureus type 5 and type 8 capsular polysaccharides
EP1828231A2 (en) Group b streptococcus
GB2478203A (en) Polypeptides and compositions for the treatment of Streptococcus agalactiae infection
BE1024282B1 (fr) Compositions immunogènes
WO2013030783A1 (en) Immunogenic proteins and compositions
AU2013202983A1 (en) Immunogenic compositions

Legal Events

Date Code Title Description
MK25 Application lapsed reg. 22.2i(2) - failure to pay acceptance fee